Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Emerging Pathogenic Mechanisms and Therapeutic Implications

Livers, Journal Year: 2025, Volume and Issue: 5(1), P. 11 - 11

Published: March 4, 2025

Non-alcoholic fatty liver disease (NAFLD), recently redefined as metabolic dysfunction-associated steatotic (MASLD), is the most common cause of chronic worldwide. Characterized by excessive hepatic fat accumulation, this encompasses a spectrum from simple steatosis to more severe forms, including steatohepatitis, fibrosis, and cirrhosis. Emerging evidence highlights pivotal role gut dysbiosis in pathogenesis MASLD. Dysbiosis disrupts gut–liver axis, an intricate communication network that regulates metabolic, immune, barrier functions. Alterations microbiota composition, increased permeability, translocation pro-inflammatory metabolites/factors have been shown trigger inflammatory fibrotic cascades, exacerbating inflammation injury. Recent studies identified microbiome signatures associated with MASLD, offering promise non-invasive diagnostic biomarkers paving way for new potential therapeutic strategies targeting dysbiosis. This review explores crucial MASLD need further targeted research field validate microbial optimize strategies. Comprehensive understanding axis may enable innovative approaches, transforming clinical management

Language: Английский

---

Gallstones in the Era of Metabolic Syndrome: Pathophysiology, Risk Prediction, and Management

Cureus, Journal Year: 2025, Volume and Issue: unknown

Published: March 13, 2025

Gallstone disease (GSD) and metabolic syndrome (MetS) are increasingly prevalent conditions with significant global health implications. Recent evidence highlights a strong epidemiological association between these disorders, driven by shared pathophysiological mechanisms. This review provides comprehensive analysis of the intricate relationship MetS GSD, focusing on role insulin resistance, dyslipidemia, obesity, gut microbiota dysbiosis in gallstone formation. An integrated model is proposed, linking disturbances to bile cholesterol supersaturation, gallbladder dysmotility, chronic inflammation. The also explores clinical implications, including risk prediction models based parameters, early detection biomarkers, targeted interventions such as lifestyle modifications, pharmacological therapies, microbiome modulation. By addressing underpinnings this synthesis offers foundation for developing preventive therapeutic strategies mitigate burden interconnected conditions. Future research directions outlined refine mechanistic insights improve outcomes.

Language: Английский

---

Significance of FXR agonists in MASLD treatment: a deep dive into lipid alteration by analytical techniques

Published: March 25, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is rapidly emerging as a global health crisis, affecting over 30% of the population and demanding urgent attention. This redefined condition, previously known non-alcoholic fatty (NAFLD), reflects deeper understanding intricate interplay between metabolic dysfunction health. At heart MASLD lies troubling accumulation triglycerides (TGs) in hepatocytes, which precipitates insulin resistance oxidative stress, ultimately leading to more severe forms like steatohepatitis (MASH). Excitingly, recent research has spotlighted farnesoid X receptor (FXR) groundbreaking therapeutic target. FXR not only regulates lipid metabolism but also combats inflammation resistance, making it potential game-changer fight against MASLD. With one FDA-approved drug, resmetirom, currently available, exploration agonists opens new avenues for innovative treatments that could revolutionize patient care. By harnessing power restore balance integrating advanced strategies lipidomics acid profiling, we stand on brink transforming how approach its associated complications, paving way healthier future. review delves into promising role combating implications related disorders, emphasizing urgency detect manage this burgeoning epidemic.

Language: Английский

---

Dietary inclusions of the brown macroalgae, Ascophyllum nodosum and Fucus vesiculosus, favourably modulate fat deposition and the caecal microbiome of obese mice

Food Bioscience, Journal Year: 2025, Volume and Issue: unknown, P. 106590 - 106590

Published: April 1, 2025

Language: Английский

---

Research Progress on the Mechanism of Bile Acids and Their Receptors in Depression

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(9), P. 4023 - 4023

Published: April 24, 2025

Depression, a highly prevalent mental disorder worldwide, arises from multifaceted interactions involving neurotransmitter imbalances, inflammatory responses, and gut–brain axis dysregulation. Emerging evidence highlights the pivotal role of bile acids (BAs) their receptors, including farnesoid X receptor (FXR), Takeda G protein-coupled 5 (TGR5), liver receptors (LXRs) in depression pathogenesis through modulation neuroinflammation, gut microbiota homeostasis, neural plasticity. Clinical investigations demonstrated altered BA profiles depressed patients, characterized by decreased primary BAs (e.g., chenodeoxycholic acid (CDCA)) elevated secondary lithocholic (LCA)), correlating with symptom severity. Preclinical studies revealed that ameliorate depressive-like behaviors via dual mechanisms: direct CNS activation indirect signaling, regulating oxidative stress, BDNF/CREB pathways. However, clinical translation faces challenges species-specific metabolism, signaling complexity, pharmacological barriers limited blood–brain barrier permeability). While FXR/TGR5 agonists exhibit neuroprotective anti-inflammatory potential, adverse effects (pruritus, dyslipidemia) require thorough safety evaluation. Future research should integrate multiomics approaches interdisciplinary strategies to develop personalized BA-targeted therapies, advancing novel treatment paradigms for depression.

Language: Английский

---

Unlocking the gut-liver axis: microbial contributions to the pathogenesis of metabolic-associated fatty liver disease

Frontiers in Microbiology, Journal Year: 2025, Volume and Issue: 16

Published: April 25, 2025

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a complex metabolic disorder characterized by hepatic lipid accumulation and subsequent inflammation. This condition closely linked to syndrome obesity, with its prevalence rising due sedentary lifestyles high-calorie diets. The pathogenesis of MAFLD involves multiple factors, including insulin resistance, lipotoxicity, oxidative stress, inflammatory responses. gut microbiota plays crucial role in development, dysbiosis contributing inflammation through various mechanisms, such as enhanced intestinal permeability the translocation bacterial products like lipopolysaccharide (LPS). Microbial metabolites, short-chain acids (SCFAs) bile acids, influence function immune responses, potential implications for progression. Specific microbiome signatures have been identified patients, offering diagnostic therapeutic targets. Moreover, gut-derived toxins, endotoxins, lipopolysaccharides, trimethylamine-N-oxide significantly damage inflammation, highlighting interplay between health. review comprehensively examines MAFLD, focusing on underlying pathogenic biomarkers, emerging microbiome-targeted strategies management.

Language: Английский

---

Gut Microbiota and Cardiovascular Diseases: Unraveling the Role of Dysbiosis and Microbial Metabolites

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(9), P. 4264 - 4264

Published: April 30, 2025

Cardiovascular diseases (CVDs), including heart failure (HF), hypertension, myocardial infarction (MI), and atherosclerosis, are increasingly linked to gut microbiota dysbiosis its metabolic byproducts. HF, affecting over 64 million individuals globally, is associated with systemic inflammation barrier dysfunction, exacerbating disease progression. Similarly, hypertension MI correlate reduced microbial diversity an abundance of pro-inflammatory bacteria, contributing vascular increased cardiovascular risk. Atherosclerosis also influenced by dysbiosis, key metabolites such as trimethylamine-N-oxide (TMAO) short-chain fatty acids (SCFAs) playing crucial roles in pathogenesis. Emerging evidence highlights the therapeutic potential natural compounds, flavonoids, omega-3 acids, resveratrol, curcumin, marine-derived bioactives, which modulate confer cardioprotective effects. These insights underscore a critical regulator health, suggesting that targeting may offer novel preventive strategies. Further research needed elucidate underlying mechanisms optimize microbiome-based interventions for improved outcomes.

Language: Английский

---

Research Progress on the Role of Gut Microbiota in Gallstone Formation through Bile Acid Metabolism

Advances in Clinical Medicine, Journal Year: 2025, Volume and Issue: 15(05), P. 758 - 767

Published: Jan. 1, 2025

Language: Английский

---

In-Vivo Insights into the Pharmacokinetic Mechanism of Algal Oil DHA-Calcium Fatty Acid Complex for Enhancing Bioavailability with Absorption and Distribution Characterization via Metabolomics

Food Bioscience, Journal Year: 2025, Volume and Issue: unknown, P. 107002 - 107002

Published: June 1, 2025

Language: Английский

---